DUBLIN--(BUSINESS WIRE)--The "Embolotherapy Market Research Report: By Product, Procedure, Indication, End - User, Geographical Outlook - Global Industry Analysis and Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.
In 2018, the global embolotherapy market generated a revenue of $3.0 billion and is expected to attain $4.8 billion by 2024, advancing at a 8% CAGR during the forecast period (2019-2024).
In terms of product, embolic agents are projected to account for the larger share of the market and register the faster growth during the forecast period. The reason for this is the rising adoption of these agents for several interventional radiology procedures.
On the basis of procedure, transcatheter arterial embolization (TAE) is predicted to advance at the fastest pace in the embolotherapy market during the forecast period.
A key factor contributing to the growth of the embolotherapy market is the rising patient pool. The increasing adoption of embolic procedures for managing several diseases is occurring due to the growing patient pool and surging healthcare spending. Moreover, the patients diagnosed at advanced and intermediate stages do not respond to curative therapies, including liver transplantation, ablation, and surgical reaction. Hence, the surging pool of patients, who are at an advanced stage of different life-threatening diseases, need embolotherapy intervention, which is resulting in the growth of the market.
Geographically, North America is predicted to account for approximately 40.0% of the embolotherapy market in 2024 due to the increasing cases of chronic diseases and surging geriatric population.
In the European region, Germany is projected to lead the embolotherapy market throughout the forecast period because of the increasing healthcare expenditure, rising awareness regarding preventive care, growing adoption of advanced healthcare techniques, and presence of established players.
China is expected to hold the largest market share in the APAC region during the forecast period due to the growing demand for minimally invasive procedures and positive reimbursement scenario.
Key Topics Covered:
Chapter 1. Research Background
Chapter 2. Research Methodology
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Definition of Market Segments
4.2 Market Dynamics
4.2.1 Trends
4.2.1.1 Increase in the number of product approvals and launches
4.2.1.2 Increasing number of acquisitions
4.2.2 Drivers
4.2.2.1 Growing patient pool for embolotherapy
4.2.2.2 Increasing prevalence of chronic and lifestyle-associated diseases
4.2.2.3 Growing medical tourism
4.2.2.4 Rising healthcare expenditure and improving healthcare infrastructure
4.2.2.5 Growing preference for MISs
4.2.2.6 Impact analysis of drivers on market forecast
4.2.3 Restraints
4.2.3.1 Risks and challenges associated with embolization
4.2.3.2 Product recalls
4.2.3.3 Dearth of skilled radiologists
4.2.3.4 Impact analysis of restraints on market forecast
4.2.4 Opportunities
4.2.4.1 Growing applications of embolic agents
4.2.4.2 Untapped market in developing economies
4.3 Porter's Five Forces Analysis
4.4 Regulatory Framework Analysis
4.4.1 U.S.
4.4.2 Europe
4.4.3 APAC
4.4.4 LATAM
4.4.5 MEA
Chapter 5. Embolotherapy Procedures in 7MM
5.1 7MM
5.2 U.S.
5.3 U.K.
5.4 Germany
5.5 France
5.6 Italy
5.7 Spain
5.8 Japan
Chapter 6. Global Market Size and Forecast
6.1 Global Market Size and Forecast
6.2 By Product
6.2.1 Embolic Agents Market, by Type
6.2.2 Embolotherapy Support Devices Market, by Type
6.3 By Procedure
6.4 By Indication
6.4.1 Embolotherapy Market for Cancer, by Type
6.4.2 Embolotherapy Market for Neurological Diseases, by Type
6.5 By End User
6.6 By Region
Chapter 7. North America Market Size and Forecast
7.1 By Product
7.1.1 Embolic Agents Market, by Type
7.1.2 Embolotherapy Support Devices Market, by Type
7.2 By Procedure
7.3 By Indication
7.3.1 Embolotherapy Market for Cancer, by Type
7.3.2 Embolotherapy Market for Neurological Diseases, by Type
7.4 By End User
7.5 By Country
7.5.1 U.S. Market Size and Forecast
7.5.1.1 By product
7.5.1.1.1 Embolic agents market, by type
7.5.1.1.2 Embolotherapy support devices market, by type
7.5.1.2 By procedure
7.5.1.3 By indication
7.5.1.3.1 Embolotherapy market for cancer, by type
7.5.1.3.2 Embolotherapy market for neurological diseases, by type
7.5.1.4 By end user
7.5.2 Canada Market Size and Forecast
7.5.2.1 By product
7.5.2.1.1 Embolic agents market, by type
7.5.2.1.2 Embolotherapy support devices market, by type
7.5.2.2 By procedure
7.5.2.3 By indication
7.5.2.3.1 Embolotherapy market for cancer, by type
7.5.2.3.2 Embolotherapy market for neurological diseases, by type
7.5.2.4 By end user
Chapter 8. Europe Market Size and Forecast
Chapter 9. APAC Market Size and Forecast
Chapter 10. LATAM Market Size and Forecast
Chapter 11. MEA Market Size and Forecast
Chapter 12. Competitive Landscape
12.1 List of Other Players
12.2 Strategic Developments of Key Players
12.2.1 Product Launches & Approvals
12.2.2 Collaborations
12.2.3 Acquisitions
12.2.4 Expansions
Chapter 13. Company Profiles
13.1 Stryker Corporation
13.2 Sirtex Medical Limited
13.3 Merit Medical Systems Inc.
13.4 Meril Life Sciences Pvt. Ltd.
13.5 Acandis GmbH
13.6 Terumo Corporation
13.7 Medtronic plc
13.8 Kaneka Corporation
13.9 Johnson & Johnson
13.10 Boston Scientific Corporation
13.11 Abbott Laboratories
13.12 Guerbet
13.13 BALT EXTRUSION SAS
For more information about this report visit https://www.researchandmarkets.com/r/29i0g3
